NASDAQ / LIVE COMPANY INTELLIGENCE

Cullinan Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCGEM
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / CGEM COVERAGE

What’s moving Cullinan Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 ...

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 ...

The story matters when it changes Cullinan Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell

Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell

Investors are testing whether Cullinan Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

The story matters when it changes Cullinan Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

The story matters when it changes Cullinan Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

The story matters when it changes Cullinan Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest CGEM filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-10 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-16 · Period 2026-06-16SEC ↗8-KMaterial company eventFiled 2026-06-10 · Period 2026-06-10SEC ↗8-KMaterial company eventFiled 2026-06-08 · Period 2026-06-06SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-04-27SEC ↗4Official SEC filingFiled 2026-07-07 · Period 2026-07-06SEC ↗
EARNINGS / QUARTERLY TRACKER

Cullinan Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.